CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...

Vertex Pharmaceuticals ... to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP). The deal comes after ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...